GAITHERSBURG, Md. — A biotechnology company has announced that a drug that could cure patients of the Ebola virus will be manufactured at its Baltimore facility.
The Baltimore Sun reports that Emergent BioSolutions made the announcement Monday. The defense department’s Biomedical Advanced Research and Development Authority is paying the Gaithersburg company $19.7 million to make a treatment for the Ebola virus.
Officials say the treatment is similar to the drug ZMapp used at the height of the Ebola outbreak last year, fighting the virus with antibodies developed from tobacco plants.
The agency is comparing other pharmaceutical companies’ Ebola antibodies to Mapp Pharmaceuticals’ ZMapp.
It is the second major Ebola-related treatment to be manufactured at the Emergent facility. Last year, Emergent produced a booster shot used with a leading Ebola vaccine candidate.
Follow WNEW on Twitter
(© Copyright 2015 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)